METTL14 (Methyltransferase 14)

METTL14 and IGF2BP1 mediate the m6A methylation of ITGB3, further promoting the deterioration of OS, providing new insights into the molecular mechanisms and potential therapeutic targets of OS.

Finally, this BGN/MDK axis could also drive the activation of normal fibroblasts into a CAF-like phenotype verified by vitro assays. In conclusion, the interplay between cancer cells and CAFs mediated by the BGN/MDK axis is a critical driver of malignancy in melanoma, highlighting it as a promising therapeutic target for intervention.

This METTL14-YAP1 axis activates CD166-EGFR-LOXL2 signaling, leading to enhanced collagen cross-linking and deposition, increased stromal stiffness, and maintenance of tumor stemness. These results identify the METTL14-YAP1 feedback loop as a core regulator of mechanical memory in pancreatic ductal adenocarcinoma, which drives stromal dysfunction and tumor progression through CD166-LOXL2 axis, and suggest targeting this loop as a potential therapeutic strategy to disrupt mechanical memory and ameliorate stiffness-induced remodeling.

Notably, m6A modifications help shape the immunosuppressive landscape in PCa by modulating immune checkpoint expression, cytokine networks, and immune cell infiltration, thereby critically influencing therapeutic responses to immunotherapy. Furthermore, this review highlights the emerging diagnostic potential and therapeutic viability of m6A-targeted strategies, offering valuable insights for future clinical translation in prostate-related diseases.

The elevated expression of YWHAH indicates its role in regulating immune balance. Together these findings suggest a potential regulatory link between TNF-α, YWHAH and METTL14 in the context of NPC.

This study indicates that XFC may upregulate the expression of lncRNA MEG3 and KLF4 by modulating METTL14-mediated m6A modification of lncRNA MEG3. Through this mechanism, XFC may regulate inflammatory responses and coagulation disorders, thereby improving SPP and exerting therapeutic effects on hyperinflammation-associated hypercoagulability in patients with OA.

METTL14 demonstrates significant predictive value regarding prognosis in BC. The METTL14 has the potential to serve as a predictive biomarker and a promising target for immunotherapy.

These results provide chemical probes for exploring the role of CamA in sporulation and colonization, with potential as antivirulence agents against C. difficile infection. Our study also introduces the first chemical probes for inhibiting bacterial CcrM and human MettL5, each of which plays key roles in their respective hosts.

GPs can effectively improve glucose-metabolism disorders, reduce inflammation, and protect pancreatic tissue in T2DM rats. The mechanisms may be associated with METTL3/14 up-regulation and FTO down-regulation, leading to enhanced m6A methylation and subsequent activation of the PI3K/AKT signaling pathway. These findings provide strong evidence for GPs regulation of epigenetic m6A RNA modification and insulin-related downstream pathways, and suggest that natural compounds targeting m6A regulation may be explored in the future for metabolic disease interventions.

See also the graphical abstract(Fig. 1).

We developed a novel predictive panel of serum m6A-related genes that could empower CRC screening and early diagnosis. METTL14, ALKBH5, YTHDC2 expression, and SOX2 protein correlate with tumor-related data and are candidates for CRC prognosis.